Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy

Conditions: Idiopathic Inflammatory Myopathy; Dermatomyositis; Anti-Synthetase Syndrome; Immune-Mediated Necrotizing Myopathy Interventions: Biological: CAB-201 following preconditioning with fludarabine and cyclophosphamide Sponsors: Cabaletta Bio Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials